Strensiq Solution
Product Images NDC 25682-016

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Strensiq (NDC 25682-016). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alexion Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Strensiq 01)

Kaplan-Meier survival curve comparing STRENSIQ (asfotase alfa) treatment with a Historical Control Group over a period of up to 528 weeks. The graph shows patient survival percentages on the vertical axis and time in weeks on the horizontal axis, indicating higher survival rates for STRENSIQ patients compared to the control group. Number of patients at risk for both groups is detailed below the x-axis across the timeline.*

FDA Label Image

Figure A (Strensiq 02)

STRENSIQ (asfotase alfa) solution for subcutaneous injection manufactured by Alexion Pharmaceuticals, Inc., shown with two small vials, two syringes with measurement markings, two alcohol prep pads, a gauze pad, and a sharps disposal container. The image displays components of the medication's administration set.*

FDA Label Image

Figure (Strensiq 03)

An image showing a close-up of hands preparing a vial of medication. One hand stabilizes the vial on a surface while the other hand removes or places the rubber stopper on the vial. The image appears instructional, related to the preparation or handling of a subcutaneous solution medication.*

FDA Label Image

Figure (Strensiq 04)

An instructional illustration showing hands preparing a syringe for injection. One hand holds the syringe barrel while the other hand pulls back the plunger. This image is related to the subcutaneous administration of a solution drug, likely STRENSIQ (asfotase alfa).*

FDA Label Image

Figure (Strensiq 05)

An instructional illustration showing two hands preparing a syringe for injection. One hand holds a vial upside down, while the other pulls the syringe plunger to draw the solution. This likely demonstrates the preparation of a subcutaneous injection solution such as STRENSIQ (asfotase alfa).*

FDA Label Image

Figure (Strensiq 06)

An instructional black and white illustration showing hands preparing a syringe for injection. One hand holds the syringe vertically, while the other hand appears to be removing a needle cap or adjusting the syringe, demonstrating a step in medication preparation or subcutaneous injection technique.*

FDA Label Image

Figure (Strensiq 07)

An instructional illustration showing two hands preparing a syringe by drawing medication from a vial, indicating the process of medication preparation for subcutaneous injection.*

FDA Label Image

Figure (Strensiq 08)

An illustration showing a hand holding a syringe with a clear barrel marked with measurement lines from 5 to 10 units. The syringe has a needle at the tip, and the illustration focuses on the fingers gripping the syringe barrel. No product branding or dosage information is visible.*

FDA Label Image

Figure (Strensiq 09)

An anatomical illustration showing recommended subcutaneous injection sites for STRENSIQ (asfotase alfa) solution on a child's body. Dark shaded areas indicate injection locations on the upper arms, abdomen, upper thighs, and upper buttocks from both front and back views.*

FDA Label Image

Figure (Strensiq 10)

Two black and white instructional illustrations showing the technique of subcutaneous injection. The images depict a hand preparing to inject solution with a syringe into the skin of an arm and the hand in the process of administering the injection, demonstrating proper angle and positioning.*

FDA Label Image

Figure (Strensiq 11)

An instructional diagram showing subcutaneous injection technique. The hand holds a syringe inserted at a 90-degree angle into the subcutaneous tissue layer above the muscle layer. An inset displays a comparison of the needle insertion angles at 90 degrees and 45 degrees.*

FDA Label Image

Figure (Strensiq 12)

An instructional illustration showing a gloved hand administering a subcutaneous injection to the forearm of a person. The syringe is positioned just above the skin, demonstrating injection technique consistent with the subcutaneous route for medication administration.*

FDA Label Image

Figure (Strensiq 13)

Illustration showing two hands administering a subcutaneous injection into the abdomen, demonstrating the injection process typically associated with a subcutaneous solution like STRENSIQ (asfotase alfa).*

FDA Label Image

Figure (Strensiq 14)

Packaging label for Strensiq (asfotase alfa) Injection 18 mg/0.45 mL solution for subcutaneous use. The carton includes twelve single-use vials, emphasizing single-use only and refrigeration requirements. Manufactured by Alexion Pharmaceuticals, Inc., the design features the Strensiq logo, dosage strength highlighted in orange, and regulatory information including NDC 25682-010-12.*

FDA Label Image

Principal Display Panel (18 mg/0.45 mL Vial Carton)

Packaging label for STRENSIQ (asfotase alfa) Injection 28 mg/0.7 mL, a subcutaneous solution by Alexion Pharmaceuticals, Inc. The carton states it is for single use only, must be refrigerated, and contains twelve single-use vials of 28 mg/0.7 mL each. Includes storage and usage instructions along with manufacturer contact details and barcode.*

FDA Label Image

Principal Display Panel (28 mg/0.7 mL Vial Carton)

Packaging label for STRENSIQ (asfotase alfa) Injection, 40 mg/mL solution for subcutaneous use from Alexion Pharmaceuticals, Inc. The carton contains twelve single-use vials of 40 mg/mL. The label includes usage instructions, storage requirements, and the National Drug Code (NDC 25682-016-12).*

FDA Label Image

Principal Display Panel (40 mg/mL Vial Carton)

STRENSIQ (asfotase alfa) Injection 80 mg/0.8 mL solution for subcutaneous use. The label indicates it is for patients 40 kg and greater, single-use only, must be refrigerated, and contains twelve single-use vials per carton. The labeler is Alexion Pharmaceuticals, Inc. with storage instructions and contact information included on the carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.